Hanmi Pharmaceutical issues safety guide for obesity drug Epe

Hanmi Pharmaceutical has issued a safety guide for the use of its GLP-1 class obesity treatment, ‘Epe’ (ingredient name: epeglenatide), following its domestic product approval in South Korea. The company emphasized the importance of providing accurate information and ensuring safe usage through its official website.

Due to rising interest in obesity treatments, Hanmi Pharmaceutical advised patients to consult medical professionals before use, noting that factors such as underlying health conditions and concurrent medications must be considered. Detailed product information is available on the company’s website, and additional safety leaflets are provided by the Korea Institute of Drug Safety & Risk Management.

Developed using Hanmi’s proprietary ‘LAPSCOVERY’ platform technology, Epe demonstrated an average weight reduction of 9.75% in a 40-week interim result of a Phase 3 clinical trial involving 448 patients. The company maintains a stable supply chain by producing the medication from raw materials to finished products at its Pyeongtaek Bio Plant.